IL2 and type 1 diabetes mellitus: A recently published multi-center, randomized, double-blind, placebo-controlled, dose-finding phase I/II study in 24 children with newly diagnosed T1D confirmed the very good tolerability and safety profile of low-dose IL-2 therapy also in children (transient and mild to moderate AEs, most frequently injection site reactions).